TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: CD36 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of CCTA for predicting cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive Predictive Value (PPV) of CCTA for ruling out cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of CCTA for ruling out cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative Predictive Value (NPV) of CCTA for ruling out cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in severity of depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: brain function activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reduction in ventricular rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Gingival Bleeding Sites at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Gingival Index (MGI) at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability of IVUS in AV Grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month disease-control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decision Making
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Progression of disease
Endpoint domain: Mortality/survival
Primary endpoint: Preliminary safety experience
Endpoint domain: Adverse events/effects
Primary endpoint: MRI pelvis examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Effectiveness and safety of treatment regimens for Giardiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC0-T) of sildenafil plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum sildenafil plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dimeglio classification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ASCVD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GCF IL-17A VOLUME
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GCF IL-17E VOLUME
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GCF TOTAL OXIDATIVE STRESS (TOS) LEVEL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCF TOTAL ANTIOXIDANT CAPACITY (TAOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition (DEXA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load in cell cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lesion BIRADS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue margin rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nominal Change From Baseline in Inflammatory Lesion (IL) Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Growth disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of uncomplicated CAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycosylated haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Understanding of the content of Nu-DESC DK
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Feasibility of the content of Nu-DESC DK
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fat mass in grams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prematurity rate
Endpoint domain: Mortality/survival
Primary endpoint: Intraepidermal nerve fiber density (IENFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Muscle strength (isokinetic strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in physical examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Results of clinical lab tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in creatine kinase activity in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in performance of knee extensor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in delayed onset of muscle soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevention of seroma complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Durable Response of Improvement in Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma Concentration of Apalutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of SL-172154
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Star Cancellation Test Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Line Bisection Test Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Picture Identification Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Pre-Specified Infusion Associated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Serious Adverse Events by 31 Days After First Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Glycemia at 180 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline Insulin at 180 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline GLP-1 at 180 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Alleviation of Influenza Signs and Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients with a deleterious mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: Postoperative infectious morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as assessed by safety laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Treatment-naïve Participants Achieving Sustained Viral Response at 12 Weeks (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing an Adverse Event (AE) During Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants That Discontinued Treatment Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Left atrial pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volumetric parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative rate urine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median disease progression free survival (mPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Heat tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Days With Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of subsidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in L-dopa 'onset' time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolongation of L-dopa 'on-time' duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal function measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patients' compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients satisfactory for the treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Practitioners' attitude for the research model
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of Bleeding and Spotting Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With Treatment Emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: EULAR individual response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of midazolam, S-warfarin, omeprazole, and caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Treatment Success at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Absolute Vital Signs (SBP, DBP and Pulse Rate) Values; Increased and Decreased Vital Signs (SBP, DBP) Values From Time-Matched Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Absolute Electrocardiogram (ECG) Values and Increased ECG Values From Time-Matched Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction with Information about Medicines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Beliefs about Medicines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knee Flexion Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk Flexion Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Participant Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in ghrelin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Days to achieve delayed primary fascial closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change on Behavioral Inhibition Scale (BIS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change on Behavioral Activation Scale (BAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dose Ascension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary Sinus Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Adherence to Refills and Medication Scale (ARMS-7) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Geometric Mean Fold-rise (GMFR) in 3 Strains of Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Titers for Serum Hemagglutination Inhibition (HI) Antibodies for 3 Strains of Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against 3 Strains of Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absence of neuronal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absence of infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absence of increased intracranial tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring for abnormal growth or tumor formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: High Frequency power in normalized units (HFnu%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cCR rate (expansion cohort)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical complete response (cCR) rate (safety lead-in)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma drug concentration versus time curve over 24 hours (AUC[0-24h]) for FP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma drug concentration (Cmax) for Salmeterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of EC D-3263 HCl
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of EC D-3263 HCl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rates (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable Disease (SD) Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive Disease (PD) Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 1 Infant Series
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): Infant Series
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After Infant Series
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprevalence of SARS-CoV-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Postoperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in TF between closed and open eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FEV1 measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Infiltration due to dialysis access cannulation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of immediate postoperative bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of short-term bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of presence of intraoral hematomas events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of presence of extraoral hematomas events
Endpoint domain: Adverse events/effects
Primary endpoint: Lower back pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Responder Status Based on PGIC Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change From Baseline in Lumbar Spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in proportion of children meeting minimum dietary diversity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioavailability of Ciclosporin (AUC(0-t), AUC(∞) and C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Subjects With One or More Subsequent Radiographic Fractures at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent of Subjects With One or More Subsequent Radiographic Fractures 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Index of cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of participants with clinically significant changes in laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of abnormal standard 12-lead electrocardiogram (ECG) findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Monetary Cost of Health Care Resources Used Per Episode of Care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of complete and major cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Phlebitis regression time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Microalbuminuria Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Italian frailty index (IFi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frailty Instrument (FIt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Everyday Memory Questionnaire (EMQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Composite of death, stroke, clinically significant bleeding event, device leak, device displacement or device thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Clinical Remission for Crohn's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinical Remission for Ulcerative Colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CSDH regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine artery Doppler indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Oximetry Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Speech disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Finger chase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nose-finger Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of Life Alzheimer's Disease (QOL-AD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Zarit Burden of Care Instrument (ZBI)
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Pain subscale of KOOS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in load-induced biomarker concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reaching hCG-administration criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of systemic reactogenicity events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of local vaccine reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients suffering grade 3 or more late mucosal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Length of Acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes